# Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-conduct-of-clinical-trials-of-medical-products-during-major-disruptions-due-to-disasters-and-public-health-emergencies/c8517058-2a59-4ca3-be07-e0046663793f > FDA guidance document: Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies. Issue date: September 21, 2023. Get complete insights and analysis. --- ## Details - Title: Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies - Communication Type: Guidance Document - Product Type: drugs - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2023-09-21 - Last Changed: 2023-10-04 - Docket Number: FDA-2023-D-3550 ## Related Documents - [Reformulating Drug Products That Contain Carbomers Manufactured With Benzene](https://www.globalkeysolutions.net/guidances/guidance-document/reformulating-drug-products-that-contain-carbomers-manufactured-with-benzene/eca61c4a-9786-4068-b4e8-00d8444874c6) - [Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4 Guidance for Industry: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/certain-ophthalmic-products-policy-regarding-compliance-with-21-cfr-part-4-guidance-for-industry-guidance-for-industry/8a04c815-2f7f-4f7e-908b-6a62504eb3e4) - [Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products: Guidance for IRBs and Clinical Investigators](https://www.globalkeysolutions.net/guidances/guidance-document/institutional-review-board-irb-review-of-individual-patient-expanded-access-submissions-for-investigational-drugs-and-biological-products-guidance-for-irbs-and-clinical-investigators/d18c103b-b568-496d-a0f1-6c8fa7abdd67)